|
US6821963B2
(en)
|
1997-07-01 |
2004-11-23 |
Warner-Lambert Company |
4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
|
|
SG2013013339A
(en)
|
2002-03-13 |
2014-12-30 |
Array Biopharma Inc |
N3 alkylated benzimidazole derivatives as mek inhibitors
|
|
US7235537B2
(en)
|
2002-03-13 |
2007-06-26 |
Array Biopharma, Inc. |
N3 alkylated benzimidazole derivatives as MEK inhibitors
|
|
WO2003077855A2
(en)
|
2002-03-13 |
2003-09-25 |
Array Biopharma, Inc |
N3 alkylated benzimidazole derivatives as mek inhibitors
|
|
GB0215823D0
(en)
|
2002-07-09 |
2002-08-14 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
US7144907B2
(en)
|
2003-09-03 |
2006-12-05 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
|
JP4931419B2
(ja)
|
2003-09-19 |
2012-05-16 |
中外製薬株式会社 |
新規4−フェニルアミノ−ベンズアルドオキシム誘導体並びにそのmek阻害剤としての使用
|
|
US7732616B2
(en)
|
2003-11-19 |
2010-06-08 |
Array Biopharma Inc. |
Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
|
|
KR101190912B1
(ko)
|
2003-11-19 |
2012-10-12 |
어레이 바이오파마 인크. |
Mek의 헤테로시클릭 억제제 및 그의 사용 방법
|
|
US7517994B2
(en)
|
2003-11-19 |
2009-04-14 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
|
MY144232A
(en)
|
2004-07-26 |
2011-08-15 |
Chugai Pharmaceutical Co Ltd |
5-substituted-2-phenylamino benzamides as mek inhibitors
|
|
EP1838675A1
(en)
|
2004-11-24 |
2007-10-03 |
Laboratoires Serono S.A. |
Novel 4-arylamino pyridone derivatives as mek inhibitors for the treatment of hyperproliferative disorders
|
|
WO2006061712A2
(en)
|
2004-12-10 |
2006-06-15 |
Pfizer Inc. |
Use of mek inhibitors in treating abnormal cell growth
|
|
US7429667B2
(en)
|
2005-01-20 |
2008-09-30 |
Ardea Biosciences, Inc. |
Phenylamino isothiazole carboxamidines as MEK inhibitors
|
|
US20060211073A1
(en)
|
2005-03-21 |
2006-09-21 |
May Earl W |
Assay for B-Raf activity based on intrinsic MEK ATPase activity
|
|
TWI441637B
(zh)
|
2005-05-18 |
2014-06-21 |
Array Biopharma Inc |
Mek雜環抑制劑及其使用方法
|
|
US8101799B2
(en)
|
2005-07-21 |
2012-01-24 |
Ardea Biosciences |
Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
|
|
US20070172843A1
(en)
|
2005-09-12 |
2007-07-26 |
Conrad Susan E |
MEK interacting protein 1 as diagnostic and therapeutic target for breast cancer treatment and prevention
|
|
NZ567140A
(en)
|
2005-10-07 |
2011-09-30 |
Exelixis Inc |
Azetidines as MEK inhibitors for the treatment of proliferative diseases
|
|
WO2007071951A1
(en)
|
2005-12-21 |
2007-06-28 |
Astrazeneca Ab |
Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer
|
|
GB0601962D0
(en)
|
2006-01-31 |
2006-03-15 |
Ucb Sa |
Therapeutic agents
|
|
US7842836B2
(en)
|
2006-04-11 |
2010-11-30 |
Ardea Biosciences |
N-aryl-N'alkyl sulfamides as MEK inhibitors
|
|
AU2007237901B2
(en)
|
2006-04-18 |
2012-07-05 |
Ardea Biosciences, Inc. |
Pyridone sulfonamides and pyridone sulfamides as MEK inhibitors
|
|
EA200802050A1
(ru)
|
2006-04-19 |
2009-04-28 |
Лаборатуар Сероно Са |
Новые гетероарилзамещенные ариламинопиридиновые производные в качестве мек ингибиторов
|
|
WO2007123939A2
(en)
|
2006-04-19 |
2007-11-01 |
Laboratoires Serono S.A. |
Novel arylamino n-heteraryls as mek inhibitors
|
|
GB0616214D0
(en)
|
2006-08-15 |
2006-09-27 |
Ucb Sa |
Therapeutic Agents
|
|
WO2008076415A1
(en)
|
2006-12-14 |
2008-06-26 |
Exelixis, Inc. |
Methods of using mek inhibitors
|
|
GB0625691D0
(en)
|
2006-12-22 |
2007-01-31 |
Astrazeneca Ab |
Combination product
|
|
ES2547303T3
(es)
|
2007-01-19 |
2015-10-05 |
Ardea Biosciences, Inc. |
Inhibidores de MEK
|
|
GB0714384D0
(en)
|
2007-07-23 |
2007-09-05 |
Ucb Pharma Sa |
theraputic agents
|
|
CA2694646C
(en)
|
2007-07-30 |
2017-09-05 |
Ardea Biosciences, Inc. |
Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
|
|
WO2009093008A1
(en)
|
2008-01-21 |
2009-07-30 |
Ucb Pharma S.A. |
Thieno-pyridine derivatives as mek inhibitors
|
|
GB0811304D0
(en)
|
2008-06-19 |
2008-07-30 |
Ucb Pharma Sa |
Therapeutic agents
|
|
JP5615274B2
(ja)
|
2008-07-01 |
2014-10-29 |
ジェネンテック, インコーポレイテッド |
Mekキナーゼインヒビターとしてのイソインドロン誘導体及びその使用方法
|
|
CA2727250A1
(en)
|
2008-07-01 |
2010-01-07 |
Genentech, Inc. |
Bicyclic heterocycles as mek kinase inhibitors
|
|
US8673919B2
(en)
|
2009-03-27 |
2014-03-18 |
Ardea Biosciences, Inc. |
Dihydropyridin sulfonamides and dihydropyridin sulfamides as MEK inhibitors
|
|
CA2814617C
(en)
|
2009-10-13 |
2017-12-19 |
Allostem Therapeutics Llc |
Novel mek inhibitors, useful in the treatment of diseases
|
|
CN102020651B
(zh)
|
2010-11-02 |
2012-07-18 |
北京赛林泰医药技术有限公司 |
6-芳基氨基吡啶酮甲酰胺mek抑制剂
|
|
US20120238599A1
(en)
|
2011-03-17 |
2012-09-20 |
Chemizon, A Division Of Optomagic Co., Ltd. |
Heterocyclic compounds as mek inhibitors
|
|
MA37405A1
(fr)
|
2012-03-14 |
2016-03-31 |
Lupin Ltd |
Composés hétérocyclyle
|
|
CA3079071C
(en)
|
2012-10-19 |
2022-06-07 |
Array Biopharma Inc. |
Preparation of crystallized benzimidazole derivative as mek inhibitor and formulation comprising same
|
|
US9556112B2
(en)
|
2012-11-15 |
2017-01-31 |
Duquesne University Of The Holy Ghost |
Carboxylic acid ester prodrug inhibitors of MEK
|
|
WO2014204263A1
(en)
|
2013-06-20 |
2014-12-24 |
The Asan Foundation |
Substituted pyridinone compounds as mek inhibitors
|
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
|
BR112017018580A2
(pt)
|
2015-03-27 |
2018-04-24 |
Jiangsu Hengrui Medicine Co., Ltd. |
p-toluenossulfonato para inibidor de mek quinase, e forma cristalina do mesmo e método de preparação para tal
|
|
US10323035B2
(en)
|
2015-04-01 |
2019-06-18 |
Crystal Pharmatech Co., Ltd. |
Co-crystal of a CDK inhibitor and an MEK inhibitor and process of preparation thereof
|
|
US10350198B2
(en)
|
2015-05-28 |
2019-07-16 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Pharmaceutical composition of MEK inhibitor and preparation method thereof
|
|
HK1255102A1
(zh)
|
2015-09-21 |
2019-08-02 |
Plexxikon Inc. |
杂环化合物及其应用
|
|
EP3558979B1
(en)
*
|
2016-12-22 |
2021-02-17 |
Boehringer Ingelheim International GmbH |
Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
|
|
PH12022551513A1
(en)
|
2019-12-20 |
2023-04-24 |
Mirati Therapeutics Inc |
Sos1 inhibitors
|
|
US20230101312A1
(en)
|
2020-02-24 |
2023-03-30 |
Mirati Therapeutics, Inc. |
Sos1 inhibitors
|
|
AU2021263742A1
(en)
*
|
2020-04-27 |
2022-09-22 |
Verastem, Inc. |
Methods of treating abnormal cell growth
|
|
EP4188383A4
(en)
|
2020-07-28 |
2025-01-08 |
Mirati Therapeutics, Inc. |
SOS1 INHIBITORS
|
|
WO2022051568A1
(en)
*
|
2020-09-04 |
2022-03-10 |
Ikena Oncology, Inc. |
Substituted 4-piperidinyl-pyrrolo[2,3-b]pyridines and related compounds and their use in treating medical conditions
|
|
WO2022051565A1
(en)
*
|
2020-09-04 |
2022-03-10 |
Ikena Oncology, Inc. |
Substituted 4-piperidinyl-quinazolines, 4-piperidinyl-pyrimidine-2-amines, and related compounds and their use in treating medical conditions
|
|
JP2024521788A
(ja)
*
|
2021-05-27 |
2024-06-04 |
ミラティ セラピューティクス, インコーポレイテッド |
併用療法
|
|
CA3221608A1
(en)
*
|
2021-06-14 |
2022-12-22 |
Kumquat Biosciences Inc. |
Fused heteroaryl compounds useful as anticancer agents
|
|
US20250059182A1
(en)
*
|
2021-06-21 |
2025-02-20 |
Mirati Therapeutics, Inc. |
Sos1 inhibitors
|